NMN Powder &Red Devil Doxorubicin

Doxorubicin (DOX) has been used as a first-line treatment for cancer and is a non-negligible revenue player for the pharmaceutical industry. Because of its toxicity and bright red appearance, Doxorubicin has long had a frightening nickname: Red Devil. In addition to most chemotherapy antibiotics’ common side effects such as nausea, vomiting, canker sores, and hair loss, DOX can also cause acute and chronic heart toxicity, which can be almost fatal.

Previous studies have shown that doxorubicin (DOX) blocks the autophagic flux in cardiomyocytes by inhibiting lysosome acidification. The V-ATPase pump maintains the acidic pH of lysosomes. However, DOX treatment also significantly depletes the NAD+ levels in cardiomyocytes.

Therefore, the study conducted by The University of Western Ontario investigated NMN Powder’s potential in preventing DOX-induced cardiotoxicity. DOX-induced cell injury and altered the lysosomal pH of H9c2 cells, an in vitro model of cardiomyocytes. And NMN attenuated these effects of DOX. Furthermore, NMN prevented the DOX-induced hyperacetylation of the V-ATPase subunit ATP6V0d1, a critical protein involved in V-ATPase activity maintenance.

In summary, NMN protects cardiomyocytes from DOX-induced toxicity by maintaining the pH of lysosomes. Thus, NMN holds potential in combating the harmful impacts of Doxorubicin on the heart.
This research is undoubtedly another great discovery in the field of NMN research. Because DOX is commonly used to treat many types of cancer, many patients who survive the battles with their disease get heart illness after treatment, impacting their daily life quality. And this paper strengthens our faith that with more in-depth and comprehensive research on NAD+ and NMN, NMN will help the people he relies on to achieve a better life and future.